2589-5559

JHEP Reports

Elsevier

View prefix report (10.1016)

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add abstracts to 1602 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

High impact1602 DOIs
2

Attach ORCID iDs across 529 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact529 DOIs
3

Deposit reference lists for 256 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact256 DOIs

DOIs for this ISSN

Showing the top 5 of 1602 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 From NASH to diabetes and from diabetes to NASH: Mechanisms… (10.1016/j.jhepr.2019.07.002)
Abstract ORCID
130.37 404
2 Macrophages in obesity and non-alcoholic fatty liver disease… (10.1016/j.jhepr.2019.02.004)
Abstract ORCID
119.63 246
3 Lifestyle modification in NAFLD/NASH: Facts and figures (10.1016/j.jhepr.2019.10.008)
Abstract ORCID
118.27 231
4 Non-alcoholic fatty liver disease: A patient guideline (10.1016/j.jhepr.2021.100322)
Abstract ORCID
114.17 191
5 Treatment of NAFLD with intermittent calorie restriction or… (10.1016/j.jhepr.2021.100256)
Abstract ORCID
111.14 166
6 NAFLD and liver transplantation: Disease burden, current man… (10.1016/j.jhepr.2020.100192)
Abstract ORCID
110.61 162
7 Portal hypertension in cirrhosis: Pathophysiological mechani… (10.1016/j.jhepr.2021.100316)
Abstract ORCID
109.79 156
8 Non-alcoholic fatty liver disease in lean individuals (10.1016/j.jhepr.2019.08.002)
Abstract ORCID
109.66 155
9 Liver toxicity as a limiting factor to the increasing use of… (10.1016/j.jhepr.2020.100170)
Abstract ORCID
108.80 149
10 The role of the gut microbiome in chronic liver disease: the… (10.1016/j.jhepr.2019.04.004)
Abstract ORCID
108.51 147
11 Epidemiology of non-alcoholic fatty liver disease and hepato… (10.1016/j.jhepr.2021.100305)
Abstract ORCID
107.92 143
12 New targets for NAFLD (10.1016/j.jhepr.2021.100346)
Abstract ORCID
107.61 141
13 Single-cell RNA sequencing of human liver reveals hepatic st… (10.1016/j.jhepr.2021.100278)
Abstract ORCID
105.19 126
14 Organoids to model liver disease (10.1016/j.jhepr.2020.100198)
Abstract ORCID
104.67 123
15 Performance of the PRO-C3 collagen neo-epitope biomarker in… (10.1016/j.jhepr.2019.06.004)
Abstract ORCID
103.96 119
16 Impact of COVID-19 on the care of patients with liver diseas… (10.1016/j.jhepr.2020.100169)
Abstract ORCID
103.96 119
17 Contribution of sarcopenia and physical inactivity to mortal… (10.1016/j.jhepr.2020.100171)
Abstract ORCID
102.65 112
18 Immunobiology of cholangiocarcinoma (10.1016/j.jhepr.2019.06.003)
Abstract ORCID
101.47 106
19 Global progress on the elimination of viral hepatitis as a m… (10.1016/j.jhepr.2019.04.002)
Abstract ORCID
100.43 101
20 Where does TIPS fit in the management of patients with cirrh… (10.1016/j.jhepr.2020.100122)
Abstract ORCID
99.56 97
21 Efficacy of rituximab in difficult-to-manage autoimmune hepa… (10.1016/j.jhepr.2019.10.005)
Abstract ORCID
98.66 93
22 Gut dysbiosis as a driver in alcohol-induced liver injury (10.1016/j.jhepr.2020.100220)
Abstract ORCID
98.19 91
23 Cost of non-alcoholic steatohepatitis in Europe and the USA:… (10.1016/j.jhepr.2020.100142)
Abstract ORCID
97.71 89
24 Novel vectors and approaches for gene therapy in liver disea… (10.1016/j.jhepr.2021.100300)
Abstract ORCID
97.22 87
25 Understanding the cellular interactome of non-alcoholic fatt… (10.1016/j.jhepr.2022.100524)
Abstract ORCID
96.98 86
26 The role of cGAS-STING signalling in liver diseases (10.1016/j.jhepr.2021.100324)
Abstract ORCID
96.72 85
27 NAFLD and MAFLD as emerging causes of HCC: A populational st… (10.1016/j.jhepr.2021.100231)
Abstract ORCID
96.21 83
28 Pcsk9 knockout exacerbates diet-induced non-alcoholic steato… (10.1016/j.jhepr.2019.10.009)
Abstract ORCID
94.88 78
29 The liver matrisome – looking beyond collagens (10.1016/j.jhepr.2020.100115)
Abstract ORCID
94.88 78
30 New frontiers in liver resection for hepatocellular carcinom… (10.1016/j.jhepr.2020.100134)
Abstract ORCID
94.88 78
31 Bile acids contribute to the development of non-alcoholic st… (10.1016/j.jhepr.2021.100387)
Abstract ORCID
94.32 76
32 Liver steatosis is a strong predictor of mortality and cance… (10.1016/j.jhepr.2019.02.002)
Abstract ORCID
94.04 75
33 Adverse muscle composition is linked to poor functional perf… (10.1016/j.jhepr.2020.100197)
Abstract ORCID
94.04 75
34 Platelets in chronic liver disease, from bench to bedside (10.1016/j.jhepr.2019.10.001)
Abstract ORCID
93.75 74
35 Granulocyte colony-stimulating factor for alcoholic hepatiti… (10.1016/j.jhepr.2020.100139)
Abstract ORCID
93.46 73
36 The oncogenic role of hepatitis delta virus in hepatocellula… (10.1016/j.jhepr.2019.05.001)
Abstract ORCID
93.17 72
37 Liver homing of clinical grade Tregs after therapeutic infus… (10.1016/j.jhepr.2019.08.001)
Abstract ORCID
93.17 72
38 Real-world experience with obeticholic acid in patients with… (10.1016/j.jhepr.2021.100248)
Abstract ORCID
92.25 69
39 Cell of origin in biliary tract cancers and clinical implica… (10.1016/j.jhepr.2021.100226)
Abstract ORCID
91.30 66
40 New insights on the role of vascular endothelial growth fact… (10.1016/j.jhepr.2021.100251)
Abstract ORCID
90.65 64
41 Quality of life and unmet needs in patients with chronic liv… (10.1016/j.jhepr.2021.100370)
Abstract ORCID
90.65 64
42 Radiotherapy for HCC: Ready for prime time? (10.1016/j.jhepr.2019.05.004)
Abstract ORCID
89.97 62
43 Weight-loss-independent benefits of exercise on liver steato… (10.1016/j.jhepr.2021.100253)
Abstract ORCID
89.62 61
44 Approach to the patient with acute severe autoimmune hepatit… (10.1016/j.jhepr.2020.100149)
Abstract ORCID
89.27 60
45 Controlled underdilation using novel VIATORR® controlled exp… (10.1016/j.jhepr.2021.100264)
Abstract ORCID
89.27 60
46 Higher phenolic acid intake independently associates with lo… (10.1016/j.jhepr.2020.100069)
Abstract ORCID
88.91 59
47 Primary liver cancer in the UK: Incidence, incidence-based m… (10.1016/j.jhepr.2021.100232)
Abstract ORCID
88.91 59
48 Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic… (10.1016/j.jhepr.2021.100237)
Abstract ORCID
88.91 59
49 Impact of COVID-19 on the management of hepatocellular carci… (10.1016/j.jhepr.2020.100199)
Abstract ORCID
88.54 58
50 Physical activity is associated with reduced risk of liver d… (10.1016/j.jhepr.2021.100263)
Abstract ORCID
88.54 58